<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02286804</url>
  </required_header>
  <id_info>
    <org_study_id>ULT-301</org_study_id>
    <nct_id>NCT02286804</nct_id>
  </id_info>
  <brief_title>Ultherapy for the Treatment of Spider Veins on the Legs</brief_title>
  <official_title>Evaluation of the Ulthera® System for Efficacious and Safe Treatment of Leg Telangiectasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ulthera, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merz North America, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Up to 30 enrolled subjects will be treated. Enrolled subjects will receive Ultherapy®&#xD;
      treatments along each length of the spider vein. Follow-up visits will occur at 30 and 60&#xD;
      days post-treatment. Study images will be obtained pre-treatment, immediately post-treatment,&#xD;
      and at each follow-up visit.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, single center, clinical trial to be conducted at one clinical&#xD;
      site. Enrolled subjects will receive up to three Ultherapy® treatments at a single depth, 14&#xD;
      days apart, using a 10-1.5mm transducer. Treatment will be provided along each length of the&#xD;
      spider vein and up to four veins will be treated per subject Maximum length of each vein&#xD;
      treated is 2cm.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Improvement of leg telangiectasia was determined by a masked, qualitative assessment of 2D photographs compared to baseline.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of leg telangiectasia</measure>
    <time_frame>60 days post-treatment</time_frame>
    <description>Determined by a masked, qualitative assessment of 2D photographs compared to baseline, based on level of clearance/improvement. Level of improvement scale:&#xD;
0 = 0% Improvement (None)&#xD;
1 = &lt; 25% Improvement (Mild)&#xD;
2 = 26 to 50% Improvement (Moderate)&#xD;
3 = 51 to 75% Improvement (Significant)&#xD;
4 = 76 to 100% Improvement (Very Significant)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinician assessment of overall aesthetic improvement</measure>
    <time_frame>30 days post-treatment</time_frame>
    <description>Overall aesthetic improvement will be assessed using the Global Aesthetic Improvement Scale:&#xD;
Very Much Improved: Optimal cosmetic result in this subject.&#xD;
Much Improved: Marked improvement in appearance from the initial condition, but not completely optimal for this subject.&#xD;
Improved: Obvious improvement in appearance from initial condition, but a re-treatment is indicated.&#xD;
No Change: The appearance is essentially the same as the original condition.&#xD;
Worse: The appearance is worse than the original condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinician assessment of overall aesthetic improvement</measure>
    <time_frame>60 days post-treatment</time_frame>
    <description>Overall aesthetic improvement will be assessed using the Global Aesthetic Improvement Scale:&#xD;
Very Much Improved: Optimal cosmetic result in this subject.&#xD;
Much Improved: Marked improvement in appearance from the initial condition, but not completely optimal for this subject.&#xD;
Improved: Obvious improvement in appearance from initial condition, but a re-treatment is indicated.&#xD;
No Change: The appearance is essentially the same as the original condition.&#xD;
Worse: The appearance is worse than the original condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject assessment of overall aesthetic improvement</measure>
    <time_frame>30 days post-treatment</time_frame>
    <description>Overall aesthetic improvement will be assessed using the Global Aesthetic Improvement Scale:&#xD;
Very Much Improved: Optimal cosmetic result in this subject.&#xD;
Much Improved: Marked improvement in appearance from the initial condition, but not completely optimal for this subject.&#xD;
Improved: Obvious improvement in appearance from initial condition, but a re-treatment is indicated.&#xD;
No Change: The appearance is essentially the same as the original condition.&#xD;
Worse: The appearance is worse than the original condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject assessment of overall aesthetic improvement</measure>
    <time_frame>60 days post-treatment</time_frame>
    <description>Overall aesthetic improvement will be assessed using the Global Aesthetic Improvement Scale:&#xD;
Very Much Improved: Optimal cosmetic result in this subject.&#xD;
Much Improved: Marked improvement in appearance from the initial condition, but not completely optimal for this subject.&#xD;
Improved: Obvious improvement in appearance from initial condition, but a re-treatment is indicated.&#xD;
No Change: The appearance is essentially the same as the original condition.&#xD;
Worse: The appearance is worse than the original condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction</measure>
    <time_frame>30 days post-treatment</time_frame>
    <description>Subjects will rate their satisfaction with the outcome of their treatment based on completion of a patient satisfaction questionnaire using the following scale:&#xD;
Very Satisfied&#xD;
Satisfied&#xD;
Slightly Satisfied&#xD;
Neither Satisfied or Dissatisfied&#xD;
Dissatisfied</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction</measure>
    <time_frame>60 days post-treatment</time_frame>
    <description>Subjects will rate their satisfaction with the outcome of their treatment based on completion of a patient satisfaction questionnaire using the following scale:&#xD;
Very Satisfied&#xD;
Satisfied&#xD;
Slightly Satisfied&#xD;
Neither Satisfied or Dissatisfied&#xD;
Dissatisfied</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Telangiectasia</condition>
  <condition>Spider Veins</condition>
  <arm_group>
    <arm_group_label>Ultherapy treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receiving Ultherapy treatment to up to 4 spider veins</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ultherapy</intervention_name>
    <description>Micro-focused ultrasound energy delivered below the surface of the skin</description>
    <arm_group_label>Ultherapy treatment</arm_group_label>
    <other_name>Ulthera System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female, age 18 years or older.&#xD;
&#xD;
          -  Subject in good health.&#xD;
&#xD;
          -  Fitzpatrick Skin Types I-III.&#xD;
&#xD;
          -  Understands and accepts the obligation not to undergo any other elective procedures,&#xD;
             i.e., laser and IPL, in the areas to be treated through the follow-up period.&#xD;
&#xD;
          -  Has up to 4 separate spider veins measuring up to 2 cm in length at a depth of&#xD;
             approximately 1.0mm.&#xD;
&#xD;
          -  Has lower extremity spider veins ≤1.0mm in diameter, linear or branching, and red,&#xD;
             pink, blue and/or purple in color, as assessed by the Investigator.&#xD;
&#xD;
          -  Willingness and ability to comply with protocol requirements, including returning for&#xD;
             follow-up visits and abstaining from exclusionary procedures for the duration of the&#xD;
             study.&#xD;
&#xD;
          -  Subjects of childbearing potential must have a negative urine pregnancy test result&#xD;
             and must not be lactating at the Screening Visit and be willing and able to use an&#xD;
             acceptable method of birth control (e.g. barrier methods used with a spermicidal&#xD;
             agent, hormonal methods, IUD, surgical sterilization, abstinence) during the study.&#xD;
             Women will not be considered of childbearing potential if one of the following&#xD;
             conditions is documented on the medical history:&#xD;
&#xD;
               1. Postmenopausal for at least 12 months prior to study;&#xD;
&#xD;
               2. Without a uterus and/or both ovaries; or&#xD;
&#xD;
               3. Bilateral tubal ligation at least six months prior to study enrollment.&#xD;
&#xD;
          -  Absence of physical or psychological conditions unacceptable to the investigator.&#xD;
&#xD;
          -  Willingness to refrain from use of aspirin, Ibuprofen, Naproxen or any other NSAID&#xD;
             prior to each study treatment and chronic use during the entire post-treatment study&#xD;
             period. Washout period, if chronic user, for 4 weeks prior to the first treatment.&#xD;
             Washout period for limited acute NSAID use, i.e., a maximum of 2-3 doses, is required&#xD;
             in the 2 weeks prior to any study treatment visit.&#xD;
&#xD;
          -  Willingness and ability to provide written consent for study-required photography and&#xD;
             adherence to photography procedures (i.e., removal of jewelry and makeup).&#xD;
&#xD;
          -  Willingness and ability to provide written informed consent and HIPAA authorization&#xD;
             prior to performance of any study-related procedure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of an active systemic or local skin disease that may affect wound healing.&#xD;
&#xD;
          -  Presence of significant varicosities or perforator veins in the area(s) to be treated.&#xD;
&#xD;
          -  Presence of large torturous varicose veins in the area(s) to be treated.&#xD;
&#xD;
          -  Significant scarring in the area(s) to be treated.&#xD;
&#xD;
          -  Open wounds or lesions in the area(s) to be treated.&#xD;
&#xD;
          -  Active implants or metallic implants in the treatment areas.&#xD;
&#xD;
          -  Presence of underlying metal hardware attached to bone from previous surgeries.&#xD;
&#xD;
          -  Inability to understand the protocol or to give informed consent.&#xD;
&#xD;
          -  BMI equal to or greater than 30.&#xD;
&#xD;
          -  History of chronic drug or alcohol abuse.&#xD;
&#xD;
          -  History of diabetes.&#xD;
&#xD;
          -  History of keloid scarring, hypertrophic scarring or abnormal wound healing.&#xD;
&#xD;
          -  History of immunosuppression/immune deficiency disorders or currently using&#xD;
             immunosuppressive medications.&#xD;
&#xD;
          -  History of thromboembolic disease, such as deep vein thrombosis (DVT).&#xD;
&#xD;
          -  History of autoimmune disease.&#xD;
&#xD;
          -  Concurrent therapy that, in the investigator's opinion, would interfere with the&#xD;
             evaluation of the safety or efficacy of the study device.&#xD;
&#xD;
          -  Subjects who anticipate the need for surgery or overnight hospitalization during the&#xD;
             study.&#xD;
&#xD;
          -  Subjects who, in the investigator's opinion, have a history of poor cooperation,&#xD;
             noncompliance with medical treatment, or unreliability.&#xD;
&#xD;
          -  Concurrent enrollment in any study involving the use of investigational devices or&#xD;
             drugs.&#xD;
&#xD;
          -  Current smoker or history of smoking in the last five years.&#xD;
&#xD;
          -  History of using the following prescription medications:&#xD;
&#xD;
               1. Accutane or other systemic retinoids within the past six months;&#xD;
&#xD;
               2. Antiplatelet agents/Anticoagulants (Coumadin, Heparin, Plavix);&#xD;
&#xD;
               3. Chronic use of non-steroidal anti-inflammatories (naproxen, ibuprofen, etc.)&#xD;
                  within the past 4 weeks;&#xD;
&#xD;
               4. Psychiatric drugs that in the investigators opinion would impair the subject from&#xD;
                  understanding the protocol requirements or understanding and signing the informed&#xD;
                  consent&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa Misell, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Ulthera, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ulthera, Inc.</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>November 5, 2014</study_first_submitted>
  <study_first_submitted_qc>November 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2014</study_first_posted>
  <disposition_first_submitted>December 13, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>December 18, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">December 19, 2017</disposition_first_posted>
  <last_update_submitted>December 18, 2017</last_update_submitted>
  <last_update_submitted_qc>December 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telangiectasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

